课题基金 / 基金详情

项目摘要

项目成果

YA HA的其他基金

相似基金

相关文献

中文摘要
翻译
项目摘要/摘要
英文摘要
PROJECT SUMMARY / ABSTRACT A long-term objective of the project is to develop PI5P4K/ inhibitors as novel pharmacological agents to treat p53-null cancers. PI5P4K and PI5P4K are homologous lipid kinases that play important roles in regulating cell metabolism and proliferation. They catalyze the phosphorylation of PI(5)P to form PI(4,5)P2. Although this is not a major synthetic route for PI(4,5)P2, their activities eliminate PI(5)P, a stress-induced lipid second messenger. Transgenic animals with PI5P4K knocked out are hypersensitive to insulin, and combined knockout with PI5P4K reduce spontaneous tumorigenesis in a mouse model of human Li-Fraumeni syndrome where tumor suppressor p53 is mutated in the germline. In preliminary studies several dihydropteridinone derivatives were identified from high throughput screening as weak inhibitors for PI5P4K. Initial syntheses, guided by X-ray crystallographic analysis of kinase inhibitor complexes, and exploiting a hydrophobic pocket unique to PI5P4K/, have yielded compounds with 50-fold greater potency for both PI5P4K and PI5P4K, and a high degree of selectivity against protein kinases. In specific aim 1, we will continue to modify the most potent inhibitor, based on a co-crystal structure of the compound with PI5P4K, and focusing on a different region of the binding pocket that undergoes conformational change. We plan to solve the crystal structure of the inhibitor with PIKfyve, a distant member of the family, in order to design analogs that do not cross-inhibit it. In specific aim 2, we study how p53(+/+) and p53(-/-) cells respond to the chemical probe. In cultured myotubes, we found that lipid kinase inhibitor disrupted cell energy homeostasis, causing AMPK activation, which may explain enhanced insulin sensitivity observed in animal studies. The possibility that lipid kinase inhibition causes cell cycle arrest by disrupting energy homeostasis in proliferating p53-/- cancer cells will be examined. The synthetic lethal interaction between PI5P4K/ and p53 will be examined by both chemical biological and genetic approaches, and direct engagement of chemical probe with the lipid kinase within proliferating tumor cells will be studied by cellular thermal shift assay (CETSA).
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
The biochemical mechanism and pharmacological inhibition of phosphatidylinositol phosphate kinases
  • 批准号:
    10711064
  • 项目类别:
  • 资助金额:
    $32.2万
  • 财政年份:
    2023
  • 负责人:
    YA HA
  • 依托单位:
Development of novel PIP4K inhibitors to treat p53-null cancer
  • 批准号:
    10260471
  • 项目类别:
  • 资助金额:
    $33.88万
  • 财政年份:
    2020
  • 负责人:
    YA HA
  • 依托单位:
Development of novel PIP4K inhibitors to treat p53-null cancer
  • 批准号:
    10427407
  • 项目类别:
  • 资助金额:
    $33.88万
  • 财政年份:
    2020
  • 负责人:
    YA HA
  • 依托单位:
Development of novel PIP4K inhibitors to treat p53-null cancer
  • 批准号:
    10033704
  • 项目类别:
  • 资助金额:
    $33.88万
  • 财政年份:
    2020
  • 负责人:
    YA HA
  • 依托单位:
国内基金
海外基金
帽结合蛋白(cap binding protein)调控乙烯信号转导的分子机制
  • 批准号:
    32170319
  • 项目类别:
    面上项目
  • 资助金额:
    58.00万元
  • 批准年份:
    2021
  • 负责人:
    董春海
  • 依托单位:
帽结合蛋白(cap binding protein)调控乙烯信号转导的分子机制
  • 批准号:
    --
  • 项目类别:
    --
  • 资助金额:
    58万元
  • 批准年份:
    2021
  • 负责人:
    董春海
  • 依托单位:
ID1 (Inhibitor of DNA binding 1) 在口蹄疫病毒感染中作用机制的研究
番茄EIN3-binding F-box蛋白2超表达诱导单性结实和果实成熟异常的机制研究
  • 批准号:
    31372080
  • 项目类别:
    面上项目
  • 资助金额:
    80.0万元
  • 批准年份:
    2013
  • 负责人:
    杨迎伍
  • 依托单位: